{"success":true,"data":{"pressRelease":{"id":"63149","rtpr_id":"nPRrF7668a","ticker":"4BB","exchange":"LSE","all_tickers":["4BB"],"title":"REG-4basebio Plc: 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board","author":"PR Newswire","published_at":"2026-06-15T06:01:11.940Z","article_body":"4basebio PLC\n\n(\"4basebio\" or the \"Company\")\n4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board \n \n * \n \n Dr. Coller \n \n \n, \n \n a Bloomberg Distinguished \n \n Professor of RNA Biology and Therapeutics \n \n ,\nbrings deep expertise to accelerate synthetic DNA and mRNA manufacturing \n \n \n* \n \nDr. Coller’s laboratory team has made seminal discoveries in the area of\nmessenger RNA stability and translation\nCAMBRIDGE, UK – June 15, 2026 \n \n – \n 4basebio PLC \n (https://www.4basebio.com/) \n (AIM: 4BB), a specialist in\nspecialist in synthetic DNA manufacturing for next-generation genomic\nmedicines and advanced therapies, today announces the appointment of Jeff\nColler, Ph.D., to its Strategic Advisory Board (SAB). A globally recognised\nfigure in mRNA biology and translation, Dr. Coller’s expertise will assist\nwith the Company’s efforts to reshape the scalable manufacturing of\nnext-generation nucleic acid therapeutics.\n\nDr. Coller joins 4basebio at a pivotal moment as the Company scales its\nsynthetic DNA technology for mRNA synthesis, AAV vector manufacturing, and\nstate-of-the-art gene editing applications. Dr. Coller’s understanding of\ntranslation efficiency and mRNA stability will help guide 4basebio’s\nstrategy to deliver optimised, high-fidelity DNA templates that maximise the\ntherapeutic potential of genetic medicines.\n\nAs 4basebio expands its capabilities, including the highly anticipated\ntransition to its new state-of-the-art Cambridge manufacturing facility, Dr.\nColler’s insights will be instrumental. His presence on the SAB reinforces\n4basebio's commitment to bridging high-impact scientific innovation with\nrobust, commercial-scale bioprocessing solutions.\n\nDr. Amy Walker, Chief Executive Officer at 4basebio, commented \n \n : \n \n “Jeff’s groundbreaking discoveries in mRNA\nstability and translation are nothing short of transformative for our\nindustry. His vision aligns perfectly with 4basebio’s bold mission to\ndismantle the bottlenecks of traditional manufacturing. With Jeff on our\nStrategic Advisory Board, we are supercharging our ability to deliver the\nhighest-performing synthetic DNA platforms to our partners - faster, purer,\nand built for the future of genetic medicine.”\n\nDr. Coller added: \n “The\nfuture of mRNA therapeutics hinges entirely on the quality and scalability of\nthe starting materials. 4basebio has engineered a truly disruptive approach to\nsynthetic DNA manufacturing that eliminates the legacy challenges of plasmid\nDNA. I am thrilled to join the Strategic Advisory Board and collaborate with a\nteam that is redefining what is biologically and commercially possible for\ngenetic medicines.”\n\nJeff Coller, Ph.D., is the Bloomberg Distinguished Professor of RNA Biology\nand Therapeutics at The Johns Hopkins University and the Inaugural Director of\nthe RNA Innovation Center. With over 30 years dedicated to the study of mRNA,\nhis pioneering research has fundamentally shifted the scientific understanding\nof gene expression, demonstrating that the genetic code acts as a master\ndeterminant of mRNA stability and transcript fate. Dr. Coller’s\ntransformative work has not only shaped foundational RNA biology but has also\naccelerated the development of life-saving mRNA therapeutics and vaccines. He\nis the co-founder of Tevard Biosciences, a founding member and Board Director\nof the Alliance for mRNA Medicines, and an elected Fellow of the American\nAssociation for the Advancement of Science (AAAS). He earned his Ph.D. in\nCellular and Molecular Biology from the University of Wisconsin-Madison and\ncompleted his postdoctoral fellowship at the Howard Hughes Medical Institute.\n\nFor further enquiries, please contact: \n \n \n\n 4basebio PLC \n Dr. Amy Walker, CEO \n +44 (0)12 2396 7943 \n Cairn Financial Advisers LLP (Nominated Adviser) \n Jo Turner / Sandy Jamieson / Ed Downes +44 (0)20 7213 0880 \n \n Cavendish Capital Markets Limited (Joint Broker) \n Geoff Nash / Nigel Birks +44 (0)20 7220 0500 \n \n RBC Capital Markets (Joint Broker) \n Kathryn Deegan / Matthew Coakes +44 (0)20 7653 4000 \n \n ICR Healthcare (Media and Investor Relations) \n Mary-Jane Elliott / Jessica Hodgson +44 (0)203 707 5700 \n\nAbout 4basebio\n\n4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the\nuse of synthetic DNA to enable next-generation therapeutics and vaccines.\nThrough its proprietary enzymatic DNA synthesis platform, 4basebio produces\nGMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability,\novercoming the limitations of plasmid-based systems. The company offers\napplication-specific DNA constructs tailored to the diverse needs of gene\ntherapies, genome editing, mRNA production, and DNA vaccines, helping partners\naccelerate proof-of-concept studies and reach clinical milestones more\nefficiently while maintaining the highest standards of safety and quality.\n\nFor more information, visit \n 4basebio.com \n (https://www.4basebio.com/) \n .\n\nForward-looking statements\n\nThis announcement may contain certain statements about the future outlook for\n4basebio. Although the directors believe their expectations are based on\nreasonable assumptions, any statements about future outlook may be influenced\nby factors that could cause actual outcomes and results to be materially\ndifferent.\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPRrF7668a","title":"REG-4basebio Plc: 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board","author":"PR Newswire","ticker":"4BB","created":"2026-06-15T06:01:11.940Z","tickers":["4BB"],"exchange":"LSE","article_body":"4basebio PLC\n\n(\"4basebio\" or the \"Company\")\n4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board \n \n * \n \n Dr. Coller \n \n \n, \n \n a Bloomberg Distinguished \n \n Professor of RNA Biology and Therapeutics \n \n ,\nbrings deep expertise to accelerate synthetic DNA and mRNA manufacturing \n \n \n* \n \nDr. Coller’s laboratory team has made seminal discoveries in the area of\nmessenger RNA stability and translation\nCAMBRIDGE, UK – June 15, 2026 \n \n – \n 4basebio PLC \n (https://www.4basebio.com/) \n (AIM: 4BB), a specialist in\nspecialist in synthetic DNA manufacturing for next-generation genomic\nmedicines and advanced therapies, today announces the appointment of Jeff\nColler, Ph.D., to its Strategic Advisory Board (SAB). A globally recognised\nfigure in mRNA biology and translation, Dr. Coller’s expertise will assist\nwith the Company’s efforts to reshape the scalable manufacturing of\nnext-generation nucleic acid therapeutics.\n\nDr. Coller joins 4basebio at a pivotal moment as the Company scales its\nsynthetic DNA technology for mRNA synthesis, AAV vector manufacturing, and\nstate-of-the-art gene editing applications. Dr. Coller’s understanding of\ntranslation efficiency and mRNA stability will help guide 4basebio’s\nstrategy to deliver optimised, high-fidelity DNA templates that maximise the\ntherapeutic potential of genetic medicines.\n\nAs 4basebio expands its capabilities, including the highly anticipated\ntransition to its new state-of-the-art Cambridge manufacturing facility, Dr.\nColler’s insights will be instrumental. His presence on the SAB reinforces\n4basebio's commitment to bridging high-impact scientific innovation with\nrobust, commercial-scale bioprocessing solutions.\n\nDr. Amy Walker, Chief Executive Officer at 4basebio, commented \n \n : \n \n “Jeff’s groundbreaking discoveries in mRNA\nstability and translation are nothing short of transformative for our\nindustry. His vision aligns perfectly with 4basebio’s bold mission to\ndismantle the bottlenecks of traditional manufacturing. With Jeff on our\nStrategic Advisory Board, we are supercharging our ability to deliver the\nhighest-performing synthetic DNA platforms to our partners - faster, purer,\nand built for the future of genetic medicine.”\n\nDr. Coller added: \n “The\nfuture of mRNA therapeutics hinges entirely on the quality and scalability of\nthe starting materials. 4basebio has engineered a truly disruptive approach to\nsynthetic DNA manufacturing that eliminates the legacy challenges of plasmid\nDNA. I am thrilled to join the Strategic Advisory Board and collaborate with a\nteam that is redefining what is biologically and commercially possible for\ngenetic medicines.”\n\nJeff Coller, Ph.D., is the Bloomberg Distinguished Professor of RNA Biology\nand Therapeutics at The Johns Hopkins University and the Inaugural Director of\nthe RNA Innovation Center. With over 30 years dedicated to the study of mRNA,\nhis pioneering research has fundamentally shifted the scientific understanding\nof gene expression, demonstrating that the genetic code acts as a master\ndeterminant of mRNA stability and transcript fate. Dr. Coller’s\ntransformative work has not only shaped foundational RNA biology but has also\naccelerated the development of life-saving mRNA therapeutics and vaccines. He\nis the co-founder of Tevard Biosciences, a founding member and Board Director\nof the Alliance for mRNA Medicines, and an elected Fellow of the American\nAssociation for the Advancement of Science (AAAS). He earned his Ph.D. in\nCellular and Molecular Biology from the University of Wisconsin-Madison and\ncompleted his postdoctoral fellowship at the Howard Hughes Medical Institute.\n\nFor further enquiries, please contact: \n \n \n\n 4basebio PLC \n Dr. Amy Walker, CEO \n +44 (0)12 2396 7943 \n Cairn Financial Advisers LLP (Nominated Adviser) \n Jo Turner / Sandy Jamieson / Ed Downes +44 (0)20 7213 0880 \n \n Cavendish Capital Markets Limited (Joint Broker) \n Geoff Nash / Nigel Birks +44 (0)20 7220 0500 \n \n RBC Capital Markets (Joint Broker) \n Kathryn Deegan / Matthew Coakes +44 (0)20 7653 4000 \n \n ICR Healthcare (Media and Investor Relations) \n Mary-Jane Elliott / Jessica Hodgson +44 (0)203 707 5700 \n\nAbout 4basebio\n\n4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the\nuse of synthetic DNA to enable next-generation therapeutics and vaccines.\nThrough its proprietary enzymatic DNA synthesis platform, 4basebio produces\nGMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability,\novercoming the limitations of plasmid-based systems. The company offers\napplication-specific DNA constructs tailored to the diverse needs of gene\ntherapies, genome editing, mRNA production, and DNA vaccines, helping partners\naccelerate proof-of-concept studies and reach clinical milestones more\nefficiently while maintaining the highest standards of safety and quality.\n\nFor more information, visit \n 4basebio.com \n (https://www.4basebio.com/) \n .\n\nForward-looking statements\n\nThis announcement may contain certain statements about the future outlook for\n4basebio. Although the directors believe their expectations are based on\nreasonable assumptions, any statements about future outlook may be influenced\nby factors that could cause actual outcomes and results to be materially\ndifferent.\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-15T06:01:11.986031128Z","server_sent_at_ms":1781503271986},"received_at":"2026-06-15T06:01:12.055Z","source_url":null},"analysis":{"id":"52576","press_release_id":"63149","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"4basebio has appointed Dr. Jeff Coller, a Bloomberg Distinguished Professor at Johns Hopkins, to its Strategic Advisory Board.\n\nDr. Coller is a globally recognized expert in mRNA biology and translation, with a track record of seminal discoveries in mRNA stability.\n\nHis appointment aims to accelerate 4basebio’s scalable manufacturing of synthetic DNA and mRNA for next-generation genomic medicines as the company transitions to its new Cambridge facility.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Scientific credibility boost: mRNA pioneer joins 4basebio advisory board."},"keyFigures":{},"quotedText":"Jeff’s groundbreaking discoveries in mRNA stability and translation are nothing short of transformative for our industry.","namedEntities":{"people":[{"name":"Dr. Jeff Coller","role":"Strategic Advisory Board Member, Bloomberg Distinguished Professor at Johns Hopkins"},{"name":"Dr. Amy Walker","role":"CEO"}],"products":["synthetic DNA","mRNA","AAV vector","gene editing applications"],"companies":[{"name":"4basebio PLC","ticker":"4BB","relationship":"filer"},{"name":"The Johns Hopkins University","relationship":"employer of appointee"},{"name":"Tevard Biosciences","relationship":"co-founded by appointee"},{"name":"Alliance for mRNA Medicines","relationship":"member organization of appointee"},{"name":"Cairn Financial Advisers LLP","relationship":"Nominated Adviser"},{"name":"Cavendish Capital Markets Limited","relationship":"Joint Broker"},{"name":"RBC Capital Markets","relationship":"Joint Broker"},{"name":"ICR Healthcare","relationship":"Media and Investor Relations"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Appointment of a highly respected scientific figure (Dr. Jeff Coller) to the Strategic Advisory Board validates the company's technology and scientific direction. While positive for credibility and strategic guidance, it is a governance/advisory move rather than a binary commercial or regulatory milestone."},"tickerRelevance":{"others":[],"primary":"4BB"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"advisory_board_appointment","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"board_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"4basebio has appointed Dr. Jeff Coller, a Bloomberg Distinguished Professor at Johns Hopkins, to its Strategic Advisory Board.\n\nDr. Coller is a globally recognized expert in mRNA biology and translation, with a track record of seminal discoveries in mRNA stability.\n\nHis appointment aims to accelerate 4basebio’s scalable manufacturing of synthetic DNA and mRNA for next-generation genomic medicines as the company transitions to its new Cambridge facility.","key_figures":{},"named_entities":{"people":[{"name":"Dr. Jeff Coller","role":"Strategic Advisory Board Member, Bloomberg Distinguished Professor at Johns Hopkins"},{"name":"Dr. Amy Walker","role":"CEO"}],"products":["synthetic DNA","mRNA","AAV vector","gene editing applications"],"companies":[{"name":"4basebio PLC","ticker":"4BB","relationship":"filer"},{"name":"The Johns Hopkins University","relationship":"employer of appointee"},{"name":"Tevard Biosciences","relationship":"co-founded by appointee"},{"name":"Alliance for mRNA Medicines","relationship":"member organization of appointee"},{"name":"Cairn Financial Advisers LLP","relationship":"Nominated Adviser"},{"name":"Cavendish Capital Markets Limited","relationship":"Joint Broker"},{"name":"RBC Capital Markets","relationship":"Joint Broker"},{"name":"ICR Healthcare","relationship":"Media and Investor Relations"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-15T06:02:34.746Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"advisory_board_appointment","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":24225,"modelName":"george-droid-qwen-72b"}}